共 99 条
[1]
Wirdefeldt K(2011)Epidemiology and etiology of Parkinson's disease: a review of the evidence Eur J Epidemiol 26 S1-58
[2]
Adami HO(2010)Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease Drugs Aging 27 295-310
[3]
Cole P(2000)Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease Arch Neurol 57 1461-1463
[4]
Trichopoulos D(2015)MDS clinical diagnostic criteria for Parkinson's disease Mov Disord 30 1591-1601
[5]
Mandel J(2006)Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update Clin Pharmacokinet 45 109-136
[6]
Wood LD(2010)Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock) Med Clin North Am 94 691-710
[7]
Kujawa K(2010)Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease CNS Drugs 24 941-968
[8]
Leurgans S(2007)Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease Lancet Neurol 6 826-829
[9]
Raman R(2008)Receptor-binding and pharmacokinetic properties of dopaminergic agonists Curr Top Med Chem 8 1049-1067
[10]
Blasucci L(2001)Vascular adrenoceptors: an update Pharmacol Rev 53 319-356